We are live on ! Find out more
NRXP icon

NRX Pharmaceuticals

17 hedge funds and large institutions have $43.4M invested in NRX Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

8% less capital inflows, than outflows

Capital inflows: $16.5M | Capital outflows: $18M

1.75% less ownership

Funds ownership: 48.58% → 46.83% (-1.7%)

15% less funds holding

Funds holding: 20 → 17 (-3)

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

Holders
17
Holders Change
-3
Holders Change %
-15%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
2
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

NRXP Hedge Fund Activity: Q2 2019 in Review

17 of the 4,627 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q2 2019, worth a combined $43.4M — down 4.5% from $45.4M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of NRXP and 4 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 4 added.

The largest buyer was Mizuho Securities USA, adding an estimated $4.25M. The largest seller was HGC Investment Management, exiting entirely with an estimated $4.86M sold.

  • 17 institutional investors held NRX Pharmaceuticals (NRXP) as of Q2 2019, down from 20 in Q1 2019.
  • Funds reported $43.4M of NRX Pharmaceuticals stock for Q2 2019, down 4.5% quarter-over-quarter.
  • 4 funds opened new NRX Pharmaceuticals positions in Q2 2019 and 7 closed out, a net change of -3 holders.
  • The largest NRX Pharmaceuticals buyer in Q2 2019 was Mizuho Securities USA, an estimated $4.25M added.
  • The largest NRX Pharmaceuticals seller in Q2 2019 was HGC Investment Management, an estimated $4.86M sold.

Based on aggregated 13F filings for Q2 2019.